|
Frank
A. Bonsal, Jr.
Mr. Bonsal was a founding member of Red
Abbey Venture Partners. Mr. Bonsal was also a founding partner of
New Enterprise Associates (NEA), one of the country’s largest
venture capital firms. During his tenure at NEA, Mr. Bonsal served
on the Board of Directors of a number of life sciences companies,
including Aspect Medical Systems, Inc. (NASDAQ: ASPM), Biopure
Corporation (NASDAQ: BPUR), Cantab Pharmaceuticals PLC (acquired by
Xenova Group PLC), GeneScreen, Inc. (acquired by Orchid Biosciences,
Inc.), IBAH, Inc. (acquired by Omnicare, Inc.), Molecular Tool, Inc.
(acquired by Orchid Biosciences, Inc.), Synaptic Pharmaceuticals
Corporation (acquired by H. Lundbeck A/S), and Vertex
Pharmaceuticals, Inc. (NASDAQ: VRTX). Additionally, Mr. Bonsal
played an active role in a number of NEA’s life sciences
investments, including Alkermes, Inc. (NASDAQ: ALKS), Anadys
Pharmaceuticals, Inc., Bethesda Research Laboratories, Inc.
(acquired by Life Technologies, Inc.), Dura Pharmaceuticals, Inc.
(acquired by Elan Corporation), GelTex Pharmaceuticals, Inc.
(acquired by Genzyme General), Genetic Therapy, Inc. (acquired by
Sandoz), Pyxis Corporation (acquired by Cardinal Health, Inc.) and
Sepracor, Inc. (NASDAQ: SEPR).
Mr. Bonsal has been a key investor and
advisor in a number of venture capital firms during his career,
including Amadeus Capital Partners, Boulder Ventures, Novak Biddle
Venture Partners, Sterling Venture Partners, Trellis Ventures,
Venturehouse and Windward Ventures.
Mr. Bonsal is a member of the Board of Trustees of the Johns Hopkins
Hospital and a member of the Johns Hopkins Hospital Endowment Board.
Also, Mr. Bonsal serves on the Board of Directors of a technology
company, Ceratech, as well as an investment advisory firm, Brown
Investment Advisory and Trust Co.
Prior to co-founding NEA in 1978, Mr. Bonsal was a General Partner
of Alex. Brown & Sons, Inc. Mr. Bonsal received a BA in Economics
from Princeton University in 1959.
Return to Management Team
About Us |
Team |
Portfolio Companies | Contact
Red Abbey Venture Partners Home |